_metastatic-castration-resistant-prostate-cancer-updates-from-asco-2019.jpg "Metastatic castration resistant prostate cancer: Updates from ASCO 2019 from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 13 min 83 sec
✓ Published: 06-Jun-2019
✓ Published: 06-Jun-2019
Description:
Dr Neal Shore, Dr Joaquin Mateo and Dr Karim Fizazi discuss the treatment and management of metastatic castration resistant prostate cancer (mCRPC). nnDr Shore provides and overview of the current treatment landscape for mCRPC before Dr Mateo summarises the TOPARP-A study and results of the TOPARP-B study presented at ASCO 2019. The panel then go on to discuss ongoing trials including PROFOUND and TRITON3 as well as summarising the ARAMIS and VISION studies.nnThe session concludes with Dr Mateo
Dr Neal Shore, Dr Joaquin Mateo and Dr Karim Fizazi discuss the treatment and management of metastatic castration resistant prostate cancer (mCRPC). nnDr Shore provides and overview of the current treatment landscape for mCRPC before Dr Mateo summarises the TOPARP-A study and results of the TOPARP-B study presented at ASCO 2019. The panel then go on to discuss ongoing trials including PROFOUND and TRITON3 as well as summarising the ARAMIS and VISION studies.nnThe session concludes with Dr Mateo
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_protein-poly-adp-ribosylation-identification-regulation-and-translation.webp "Speaker:nYonghao Yu, PhDnUniversity of Texas, SouthwesternnnOur understanding of how the biology of various diseases relates to the central dogma that DNA encodes RNA, which encodes protein has been buoyed by rapid technological advances in DNA and RNA sequencing and has led to some of the first advances in personalized medicine. However, characterization of the final and arguably most actionable element of the central dogma, protein, has lagged behind. We are interested in developing mass spect")
⏲ 44 min 93 sec ✓ 24-Sep-2020
_parp-inhibitors-for-metastatic-breast-cancer.webp "Prof Michael Untch speaks to ecancer at ESMO 2019 in Barcelona about some of the trials covering PARP inhibitors for metastatic breast cancer.nnProf Untch outlines the OlympiAD and EMBRACA trials for patients with BRCA mutations, both with positive results.nnHe also touches on the BrighTNess study which involves a new PARP inhibitor, veliparib.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php")
_dora-using-olaparib-alone-or-with-durvalumab-in-platinum-responsive-advanced-triple-negative-breast-cancer.webp "Dr Tira Tan speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the phase II DORA study. nnShe explains that the trial uses the PARP inhibitor olaparib alone or in combination with the PD-L1 inhibitor durvalumab to treat patients with platinum responsive advanced triple-negative breast cancer, thereby using a maintenance strategy to reduce the toxicities experienced by patients.nnDr Tan says that they are expecting some correlative work to come out of")
⏲ 2 min 12 sec ✓ 03-Jun-2019
_parp-inhibitors-in-prostate-cancer-and-latest-developments.webp "Prof. Neeraj Agarwal takes a look at poly-ADP ribose polymerase inhibitors (PARPi's) in prostate cancer and in particular the latest clinical developments.")
_targeting-advanced-prostate-cancer-with-parp-inhibitors-who-when-and-how.webp "GU CONNECT members, Assoc. Prof. Tanya Dorff (USA) and Prof. Gerhardt Attard (UK) along with guest expert Prof. Fred Saad (Canada) were joined by participants from around the world to discuss targeting advanced prostate cancer with PARP inhibitors: Who, When and How?n nThere was a very interesting and dynamic discussion about:nThe efficacy and safety profiles of PARP inhibitors for patients with prostate cancer and the safety profile in other tumour typesnImplementation of testing strategies to")
⏲ 31 min 97 sec ✓ 15-Mar-2022
_advances-in-prostate-cancer-in-the-last-10-years-and-a-glimpse-to-the-future.webp "Prof Laura-Maria Krabbe (University of Muenster Medical Center, Muenster, Germany), Prof Karim Fizazi (Institut Gustave Roussy, Villejuif, France) and Prof Johann De Bono (The Institute of Cancer Research, London, UK) discuss the advances in prostate cancer in the last 10 years and offer a glimpse of the future. nnInitially, Prof Krabbe discusses abiraterone and enzalutamide in mCRPC (post docetaxel and pre docetaxel) and their impact for mCRPC care. Prof Fizazi and Prof De Bono then discuss the")
⏲ 20 min 30 sec ✓ 24-Sep-2021
_parp-inhibitor-olaparib-added-to-bevacizumab-benefits-women-with-ovarian-cancer-with-and-without-a-brca-mutation.webp "Prof Isabelle Ray-Coquard presents data from the PAOLA-1/ENGOT-ov25 trial during a press conference at the 2019 ESMO congress.nnThis was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.necancer.org/account/register.php")
⏲ 3 min 31 sec ✓ 28-Sep-2019
_asco-2023-latest-in-parp-inhibitors-in-prostate-cancer.webp "Prof Rana McKay (The University of California, San Diego, USA), Prof Gunhild von Amsberg (Martini Clinic, Hamburg, Germany) and Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France) discuss the latest in PARP inhibitors in prostate cancer. nnThe panel analyses the secondary datasets from trials such as PROPEL 2, TALAPRO 2 and MAGNITUDE and discuss how it impacts our understanding of best practice with the use of PARP inhibitors in prostate cancer. nnThey cover the r")
_protein-poly-adp-ribosylation-identification-regulation-and-translation.jpg)
_parp-inhibitors-for-metastatic-breast-cancer.jpg)
_dora-using-olaparib-alone-or-with-durvalumab-in-platinum-responsive-advanced-triple-negative-breast-cancer.jpg)
_parp-inhibitors-in-prostate-cancer-and-latest-developments.jpg)
_targeting-advanced-prostate-cancer-with-parp-inhibitors-who-when-and-how.jpg)
_advances-in-prostate-cancer-in-the-last-10-years-and-a-glimpse-to-the-future.jpg)
_parp-inhibitor-olaparib-added-to-bevacizumab-benefits-women-with-ovarian-cancer-with-and-without-a-brca-mutation.jpg)
_asco-2023-latest-in-parp-inhibitors-in-prostate-cancer.jpg)
![[+]](/images/menu.gif){kind=small}